In short. A suspected vascular occlusion is assessed at the bedside and quickly, because each finding changes what is done. Assessment is clinical and does not wait for imaging: substance, areas and timing are established, skin and eye examined, and a dissolvable filler treated with its enzyme at once. It ends in a plan, an interval and a contact.
Key points
- Every finding answers one of two questions: is circulation intact, and is anything dissolvable.
- Substance class decides whether the dissolving enzyme is available at all.
- Glabella, nose, temple and tear trough share a blood supply with the eye.
- Vision, pupil, eyelid position and eye movements are checked early.
- The assessment ends in a plan, an interval and a contact, not reassurance.
What happens first when an occlusion is suspected?
A suspected occlusion is assessed at the bedside, and quickly, because the answers change what is done rather than only what is recorded. Every part of the assessment answers one of two questions: is the circulation to this skin and this eye intact, and is there anything that can be dissolved. The first decisions are clinical, and they are made at once.
Which three facts are established before anything is examined?
The first questions are which substance was injected, into which areas, and when. Only a dissolvable gel filler can be broken down with an enzyme, so the substance class decides whether the main treatment is available at all. The areas treated decide how much territory is at risk, because an injection at the glabella, the nose, the temple or the tear trough shares a blood supply with the eye. The time sets the interval already elapsed.
What is looked for in the skin and the eye?
The skin is examined for blanching, a mottled or dusky colour, a lacy or net-like pattern, and coldness to touch. Capillary refill is checked, and the boundary of anything that has changed is marked and photographed, because the boundary moves. Vision is tested, the pupil and its reaction to light are examined, and eyelid position and eye movements are checked. A change in vision, a drooping eyelid, or pain around the eye is an emergency of its own and brings an ophthalmology assessment early.
Pain is a finding, not a symptom to be managed first
Severe pain out of proportion to the injection, and pain that is climbing rather than settling, are recorded as findings. They are measured at each contact because the direction they are moving in carries more information than their severity at any one moment.
Each step in the first hours answers a question, and the table sets out what each finding decides.
| Step | What is checked | What it decides |
|---|---|---|
| Substance and areas | Which product class was used; glabella, nose, temple or tear trough | Whether the enzyme is available; how much territory is at risk |
| Time | The interval since the injection | How much time has already elapsed |
| Skin | Blanching, mottled or dusky colour, lacy pattern, coldness, capillary refill | Whether circulation to the skin is intact |
| Boundary | The edge of changed skin, marked and photographed | A record to compare as the boundary moves |
| Eye | Vision, pupil and light reaction, eyelid position, eye movements | Whether the eye is involved and needs ophthalmology |
| Pain | Severity against expectation, and its direction at each contact | A finding tracked over time, not managed first |
| Product class | Whether the filler is of the enzyme-dissolvable class | Prompt enzyme, not confined to the injection point |
| Remainder | Warmth, hydration, pain control, protection, burns or oculoplastic care | A plan, an interval and a contact |
Dissolving what can be dissolved
Where a filler of the enzyme-dissolvable class is responsible, the enzyme that dissolves it is given promptly. Its use is not confined to the point of injection, because the material has travelled and the territory at risk is larger than the needle track. Two things are said plainly. The enzyme removes the product, which removes the cause; it does not repair tissue that has already lost its blood supply, and the skin affected may still blister, darken or be lost. Nor is it available for fillers outside that class: biostimulators, polycaprolactone fillers and calcium-based fillers cannot be broken down with it.
What makes up the rest of the first hours?
Warmth, hydration, pain control, protection of the area and, where it is needed, care from a burns or oculoplastic service make up the remainder. The assessment ends in a plan and an interval rather than in reassurance: what has been done, what is being watched for, and who to contact in between.
Seek emergency care now if
- Pain is out of proportion to the injection, or is worsening rather than settling.
- Skin is white, grey, mottled or dusky, shows a lacy pattern, or feels cold.
- There is any change in vision, a drooping eyelid, or blistering or darkening skin.
What should a patient bring?
Bring the treatment record with you if you can. Which substance, which areas and when are the three facts that make the first minutes of the assessment productive instead of investigative.
Sources
- NICE — guidance on cosmetic procedures and injectable fillers
- Royal College of Ophthalmologists — guidance on visual loss after facial filler
- British Association of Plastic, Reconstructive and Aesthetic Surgeons — guidance on injectable filler complications
Frequently asked questions
What happens first when I arrive with a suspected occlusion?
The substance and the areas treated are established first, because they decide what can be done, then the skin is examined for colour, temperature and refill. Vision, the pupil, eyelid position and eye movements are checked, and the pain is recorded against what would be expected. The changed area is marked and photographed so that its progress can be judged.
What is the enzyme that dissolves filler?
It is an enzyme that dissolves one class of gel filler, and it works only on fillers of that dissolvable class. Where such a product is responsible it is used promptly, and its use is not limited to the injection point because the territory at risk may be larger. It acts on the product rather than on tissue that has already lost its blood supply.
What if the filler was not of the dissolvable class?
Then there is nothing to dissolve, and treatment is directed at supporting the circulation and the skin, protecting the eye where it is involved, and managing what follows. Biostimulators, polycaprolactone fillers and calcium-based fillers cannot be broken down with that enzyme. This is why knowing which substance was used matters so much at the start.
Risks & Limitations
- The site of the injection is not the site of the damage: filler that enters an artery is carried by the blood flow and lodges downstream.
- Only a filler of the enzyme-dissolvable class can be dissolved. Biostimulators, polycaprolactone and calcium-based fillers cannot.
- Dissolving the product removes the cause; it does not repair tissue that has already lost its blood supply.
- The glabella, nose, forehead, temple and tear trough share a blood supply with the eye, which is why they are treated with particular care.
- A change in vision after a facial injection is an emergency in which minutes matter, and recovery cannot be assumed.
- Where skin or vision has been lost, later treatment can improve an area but does not restore what was there before.
When to Seek Care
- Severe pain out of proportion to the injection, or pain that keeps worsening — seek emergency care now.
- Skin turning white, grey, mottled or dusky, a lacy or blotchy pattern, or skin that feels cold — seek emergency care now.
- Any change in vision, a drooping eyelid, or pain and swelling around the eye — seek emergency care now; minutes matter.
- Blistering, peeling or darkening skin over a treated area — seek emergency care now.
- A severe headache, or weakness or numbness on one side of the body — seek emergency care now and call emergency services.
- A reaction that is not settling but is not in this list — contact your treating team the same day.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — injectable filler safety guidance
- U.S. Food and Drug Administration (FDA) — dermal filler safety information
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. Discuss your own case with a qualified clinician. To arrange an assessment at Chongqing West District Hospital, see Contact & Consultation.